Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.

Scot GargPly ChichareonNorihiro KogameKuniaki TakahashiRodrigo ModoloChun-Chin Chang Mariusz TomaniakFarzin Fath-OrdoubadiRichard A AndersonKeith G OldroydRod H StablesNeville KukrejaSaqib ChowdharyGavin GalaskoStephen HooleAzfar ZamanChristian W HammPhilippe G StegPeter JüniMarco ValgimigliStephan WindeckerYoshinobu OnumaPatrick W J C Serruys

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)

The poorer outcomes in patients with established CVD are not mitigated by prolonged monotherapy with a potent P2Y12 inhibitor suggesting a greater need to focus on modifiable risk factors.

Keyphrases

cardiovascular disease
risk factors
phase iii
open label
phase ii
clinical trial
double blind
study protocol
type diabetes
randomized controlled trial
placebo controlled
metabolic syndrome
combination therapy
cardiovascular risk factors
glycemic control